Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2016 - 2025)

Lineage Cell Therapeutics' Asset Utilization Ratio history spans 15 years, with the latest figure at 0.14 for Q4 2025.

  • For Q4 2025, Asset Utilization Ratio rose 58.99% year-over-year to 0.14; the TTM value through Dec 2025 reached 0.14, up 58.99%, while the annual FY2025 figure was 0.13, 45.39% up from the prior year.
  • Asset Utilization Ratio reached 0.14 in Q4 2025 per LCTX's latest filing, up from 0.12 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.47 in Q3 2022 to a low of 0.01 in Q2 2021.
  • Average Asset Utilization Ratio over 5 years is 0.15, with a median of 0.09 recorded in 2023.
  • Peak YoY movement for Asset Utilization Ratio: surged 3078.23% in 2022, then plummeted 82.87% in 2023.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.35 in 2021, then plummeted by 66.82% to 0.12 in 2022, then dropped by 25.17% to 0.09 in 2023, then increased by 4.86% to 0.09 in 2024, then soared by 58.99% to 0.14 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Asset Utilization Ratio are 0.14 (Q4 2025), 0.12 (Q3 2025), and 0.11 (Q2 2025).